SCHEMBL10656853

SCHEMBL10656853

CCC(CC)OC(=O)n1cc(F)c(=O)[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ MAPK3 P27361 1/20 0.49
▸ ASAH1 Q13510 1/20 0.49
▸ SQOR Q9Y6N5 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ GRIA1 P42261 1/20 0.45
▸ GRIA2 P42262 1/20 0.45
▸ GRIA3 P42263 1/20 0.45
▸ GRIA4 P48058 1/20 0.45
▸ GRIK5 Q16478 1/20 0.45
▸ KMT2A Q03164 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23322830 0.84 LMNA (0.46) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11024545 0.82 LMNA (0.61) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11040533 0.81 LMNA (0.44) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11159032 0.81 LMNA (0.44) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL25965763 0.79 LMNA (0.42) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL10656213 0.76 SMN1; SMN2 (0.57) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11771756 0.75 LMNA (0.50) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL12500772 0.75 LMNA (0.56) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL15616807 0.75 LMNA (0.46) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL3823927 0.74 SMN1; SMN2 (0.62) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0265506-A1 A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER FARMACEUTISK LABORATORIUM FERRING A/S (DK) 1988-05-04 — — EP claimed
WO-1987006581-A1 A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER FARMACEUTISK LABORATORIUM FERRING A/S (DK) 1987-11-05 — — WO claimed
EP-0265506-A1 A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER FARMACEUTISK LABORATORIUM FERRING A/S (DK) 1988-05-04 — — EP disclosed
WO-1987006581-A1 A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER FARMACEUTISK LABORATORIUM FERRING A/S (DK) 1987-11-05 — — WO disclosed
Send feedback